Where delivery transforms treatment.

Latus develops innovative gene therapy candidates that use precision delivery with the goal of improving the lives of patients.

The therapy isn’t just the gene — it's also the vehicle.

AAV (Adeno-Associated Virus) is a non-pathogenic virus commonly used in gene therapy to potentially deliver therapeutic genes to targeted cells. Traditional AAV approaches often face challenges due to a lack of potency and specificity, requiring high doses that lead to unwanted immune responses, tissue toxicities and difficulties with scalable manufacturing.

By screening tens of millions of novel capsid variants, we’re seeking to advance the standard for precision gene therapy.

Through deploying massively-paralleled, high throughput and unbiased screening of AAV capsids–we're mapping the course for the future of CNS treatment development. Designed to accurately target tissues and reduce unwanted interactions, our technology aims to minimize the risks of immunogenicity and toxicity, and to deliver the payload exactly where it's needed.

Pursuing Efficacy

Striving to Increase Substructure– and Cell-specific Targeting in the CNS

Prioritizing Well-Being

Aiming to Limit or Avoid On– and Off-Tissue Toxicity

Optimizing Administration

Designed for Direct Delivery with Conventional Clinical Techniques

Lead programs

Our one-time gene therapy candidates are designed to fundamentally change how many CNS diseases are treated.

Existing CNS treatment paradigms may require frequent administrations and have side effects that are sometimes worse than the disease. Our candidates are being designed to meaningfully reduce toxicity and improve quality of care for patients.

A mother and father with their daughter squeezed lovingly between them. The father is kissing their daughter on the cheek and the mother is smiling.

Huntington’s Disease

“HD remains a devastating, incurable genetic brain disease, for which we desperately need effective interventions. A breakthrough would be transformative for affected patients and families worldwide.”
—HD Clinician

CLN2

“I really hope we can find a way to slow down this disease. No parent wants to see their kid go through endless hospital visits, the pain of treatments, or spend their days in a hospital bed. We just want more happy, normal days at home, more laughter, and less tears—more time being a family without the constant stress of medical issues.”
—Caregiver

pipeline

The specificity of our capsids allows us to effectively target a broad range of CNS disorders.

AAV-EP+

Tissues of interest

Ependyma/neurons

Routes of Administration

icv

Targets

Lysosomal Storage Disorders

Secreted Protein

Cross-Correction

Secreted Protein Therapeutics

AAV-DB

Tissues of interest

Deep brain

Routes of Administration

ip

Targets

Parkinson’s Disease

Huntington’s Disease

AAV-Ear

Tissues of interest

Inner ear/hair cells

Routes of Administration

ICV

Targets

Genetic hearing loss

AAV-PN

Tissues of interest

Pan-neuronal

Routes of Administration

icv

Targets

Angelman Syndrome

Rett Syndrome

Frontotemporal dementia

Alzheimer’s Disease

AAV-CB

Tissues of interest

Cerebellum

Routes of Administration

icv, ip

Targets

Spinocereberal ataxias

Friedreich Ataxia

AAV-Vasc

Tissues of interest

Brain microvasculature

Routes of Administration

iv

Targets

Glut1 deficiency

Lysosomal Storage Disorders

PArtners

Partners in Progress: Battling Huntington's with the HDF

Gene therapy–precisely delivered.

Take a step forward in developing the next generation of potentially curative medicines for patients.

Want to join our team?

Careers